SMILES stringlengths 71 300 | POI_Name stringclasses 164
values | POI_Sequence stringclasses 133
values | Ligase_Name stringclasses 9
values | Cell_Line stringclasses 155
values | Value_Type stringclasses 2
values | Value_Unit stringclasses 2
values | Value float64 -53.5 100k | Value_Error float64 1 81.3 ⌀ | Value_Range_Min float64 0.1 1.49k ⌀ | Value_Range_Max float64 0.76 1.99k ⌀ | Value_Concentration float64 0.1 100 ⌀ | Assay_Time float64 2 96 ⌀ | Value_Operator stringclasses 5
values | Value_Category stringclasses 2
values | Value_Concentration_Unit stringclasses 2
values | Modality stringclasses 1
value | POI_UniProt stringclasses 131
values | Ligase_UniProt stringclasses 11
values | Ligase_Sequence stringclasses 11
values | Cell_Line_ID stringclasses 154
values | Cell_Line_Species stringclasses 4
values | Reference stringclasses 367
values | Description stringclasses 501
values | Database stringclasses 6
values | Assay stringclasses 21
values | TPD_ID stringlengths 10 10 ⌀ | Cell_Line_Description stringclasses 151
values | POI_Cluster int64 -1 37 | SMILES_Held_Out bool 2
classes | SMILES_Scaffold_Cluster int64 -1 2.35k | SMILES_Butina_Cluster int64 -1 278 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
C#Cc1c(F)ccc2cc(O)cc(-c3nc(O)c4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-6RLL4D | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3nc(O)c4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 10 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-6RLL4D | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3nc(OC)c4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(C7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-R97O5I | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 1 | 222 |
C#Cc1c(F)ccc2cc(O)cc(-c3nc(OC)c4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(C7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-R97O5I | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 1 | 222 |
C#Cc1c(F)ccc2cc(O)cc(-c3nc(OC)c4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-OMKS0Z | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3nc(OC)c4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-OMKS0Z | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3nc(OC)c4c(N5CC6CCC(C5)N6C(=O)C(F)(F)F)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 550 | null | 100 | 1,000 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-V7I2WM | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3nc(OC)c4c(N5CC6CCC(C5)N6C(=O)C(F)(F)F)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-V7I2WM | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN(C)C6CCC7(CC6)CN(c6ccc(C(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)N[C@@H](C)c8ccc(-c9scnc9C)cc8)C(C)(C)C)cc6)C7)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 21 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-BJDZ82 | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 2 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN(C)CC6CC7(C6)CN(c6ccc(C(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)N[C@@H](C)c8ccc(-c9scnc9C)cc8)C(C)(C)C)cc6)C7)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 52 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-XJ3ZX9 | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 3 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN(C)CCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCc6ccc(-c7scnc7C)cc6)C(C)(C)C)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 54 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-F4M7CY | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 4 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN(C)Cc6ccc(OCCC(=O)N[C@H](C(=O)N7C[C@H](O)C[C@H]7C(=O)NCc7ccc(-c8scnc8C)cc7)C(C)(C)C)nc6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 51 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-GVUFF9 | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 5 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CC(C#Cc7ccc8c(c7)CN(C7CCC(=O)NC7=O)C8=O)C6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-7XE4D9 | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 6 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CC(C#Cc7ccc8c(c7)CN(C7CCC(=O)NC7=O)C8=O)C6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-7XE4D9 | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 6 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CC7(CCN(c8ccc(C(=O)N[C@H](C(=O)N9C[C@H](O)C[C@H]9C(=O)N[C@@H](C)c9ccc(-c%10scnc%10C)cc9)C(C)(C)C)cc8)CC7)C6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 72 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-79X3KH | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 7 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(C7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 550 | null | 100 | 1,000 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-O9G3ZB | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 8 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(C7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-O9G3ZB | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 8 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(CN7CCC(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-HEM71P | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 9 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(CN7CCC(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-HEM71P | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 9 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(CN7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-CB461N | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 10 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(CN7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-CB461N | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 10 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(COc7ccc(C(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)NCc8ccc(-c9scnc9C)cc8)C(C)(C)C)cc7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 24 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-WPMMAJ | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 11 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(Cc7ccc(C(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)NCc8ccc(-c9scnc9C)cc8)C(C)(C)C)cc7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 55 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-R66TBE | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 12 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(N7CCC(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-Q0GL7U | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 13 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(N7CCC(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-Q0GL7U | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 13 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC7(CC6)CCN(c6ccc(C(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)N[C@@H](C)c8ccc(-c9scnc9C)cc8)C(C)(C)C)cc6)CC7)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 29 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-1EL1DC | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 14 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC7(CC6)CN(Oc6ccc(C(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)N[C@@H](C)c8ccc(-c9scnc9C)cc8)C(C)(C)C)cc6)C7)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 40 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-H5YY14 | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 15 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC7(CC6)CN(c6ccc(C(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)N[C@@H](C)c8ccc(-c9scnc9C)cc8)C(C)(C)C)cc6)C7)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 20 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-7ZHOU5 | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 16 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC7(CC6)CN(c6ccc(C(=O)N[C@H](C(=O)N8C[C@H](O)C[C@H]8C(=O)N[C@H](C)c8ccc(-c9scnc9C)cc8)C(C)(C)C)cn6)C7)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | AGS | DC50 | nM | 24 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0139 | Homo sapiens | KRAS G12D DEGRADATION AGENT AND MEDICAL USE THEREOF (patent) | In this experiment, the ability of compounds to degrade KRAS G12D was detected by intracellular immunoblotting. The AGS cells in good growth condition and in the logarithmic growth phase were plated in a 96-well transparent bottom black plate, so that the number of cells in each well was 5×10?; cultured overnight at 37... | TPDdb | Western Blot | TPD-Y988UK | African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12%.
Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutat... | -1 | false | 17 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(C7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-AKAEQ5 | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 18 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(C7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-AKAEQ5 | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 18 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC#Cc7ccc8c(c7)CN(C7CCC(=O)NC7=O)C8=O)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-QTS3OL | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 19 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC#Cc7ccc8c(c7)CN(C7CCC(=O)NC7=O)C8=O)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-QTS3OL | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 19 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(=O)n(C%10CCC(=O)NC%10=O)ncc9c8)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-Z06K1K | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 20 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(=O)n(C%10CCC(=O)NC%10=O)ncc9c8)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-Z06K1K | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 20 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-E6B6YH | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-E6B6YH | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)C7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-7KZ6LE | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 21 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)C7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-7KZ6LE | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 21 | 41 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6C(=O)C(F)(F)F)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 550 | null | 100 | 1,000 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-PPJMKT | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6C(=O)C(F)(F)F)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-PPJMKT | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6C(=O)CC)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-T6TCFY | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 0 |
C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6C(=O)CC)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 10 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-T6TCFY | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 0 |
C#Cc1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCCN(CC)CCOc2ccc(C(=O)c3c(-c4ccc(O)cc4)sc4cc(O)ccc34)cc2)C(C)(C)C)cc1 | ESR1 | MTMTLHTKASGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPAVYNYPEGAAYEFNAAAAANAQVYGQTGLPYGPGSEAAAFGSNGLGGFPPLNSVSPSPLMLLHPPPQLSPFLQPHGQQVPYYLENEPSGYTVREAGPPAFYRPNSDNRRQGGRERLASTNDKGSMAMESAKETRYCAVCNDYASGYHYGVWSCEGCKAFFKRSIQGHNDYMCPATNQCTIDKNRRKSCQACRLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAANLWPSPLMIKRSKKNSLALSLTADQMVSALL... | VHL | MCF-7 | Dmax | % | 10 | null | null | null | null | 4 | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P03372 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0031 | Homo sapiens | https://pubmed.ncbi.nlm.nih.gov/30990042/ | EC50 of ligand was measured in MCF7 cells. DCmax was measured in 1 nM (at 10 nM 76 %). | PROTACpedia | null | null | African=0.74%; Native American=0%; East Asian, North=4.2%; East Asian, South=0%; South Asian=0%; European, North=56.91%; European, South=38.15%.
Helen Marion Mallon (sister Catherine Frances), the patient from which this cell line is derived was a nun at the Immaculate Heart of Mary convent in Monroe, Michigan (CelloPu... | 15 | false | 22 | 0 |
C#Cc1ccc([C@H](CC(=O)N2CCC(C#Cc3ccc(C(=O)N[C@H]4C(C)(C)[C@H](Oc5ccc(C#N)c(Cl)c5)C4(C)C)cc3)CC2)NC(=O)[C@H]2C[C@H](O)CN2C(=O)[C@@H](c2cc(C)no2)C(C)C)cc1 | AR | MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPPGASLLLLQQQQQQQQQQQQQQQQQQQQQQQETSPRQQQQQQGEDGSPQAHRRGPTGYLVLDEEQQPSQPQSALECHPERGCVPEPGAAVAASKGLPQQLPAPPDEDDSAAPSTLSLLGPTFPGLSSCSADLKDILSEASTMQLLQQQQQEAVSEGSSSGRAREASGAPTSSKDNYLGGTSTISDNAKELCKAVSVSMGLGVEALEHLSPGEQLRGDCMYAPLLGVPPAVRPTPCAPLAECKGSLLDDSAGKSTEDTAEYSPFKGGYTKGL... | VHL | LNCaP | Dmax | % | 99 | null | null | null | null | 6 | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P10275 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0395 | Homo sapiens | https://pubmed.ncbi.nlm.nih.gov/31804827/ | null | PROTACpedia | null | null | Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01
Instable (MSI).
Metastatic; Left supraclavicular lymph node;
Caucasian.
Space-flown cell line (cellonaut).
Cancer cell line | 16 | false | 23 | 70 |
C#Cc1ccc([C@H](CC(=O)N2CCC(N3CCC(C#Cc4ccc(C(=O)N[C@H]5C(C)(C)[C@H](Oc6ccc(C#N)c(Cl)c6)C5(C)C)cc4)CC3)CC2)NC(=O)[C@H]2C[C@H](O)CN2C(=O)[C@@H](c2cc(C)no2)C(C)C)cc1 | AR | MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPPGASLLLLQQQQQQQQQQQQQQQQQQQQQQQETSPRQQQQQQGEDGSPQAHRRGPTGYLVLDEEQQPSQPQSALECHPERGCVPEPGAAVAASKGLPQQLPAPPDEDDSAAPSTLSLLGPTFPGLSSCSADLKDILSEASTMQLLQQQQQEAVSEGSSSGRAREASGAPTSSKDNYLGGTSTISDNAKELCKAVSVSMGLGVEALEHLSPGEQLRGDCMYAPLLGVPPAVRPTPCAPLAECKGSLLDDSAGKSTEDTAEYSPFKGGYTKGL... | VHL | LNCaP | Dmax | % | 99 | null | null | null | null | 6 | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P10275 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0395 | Homo sapiens | https://pubmed.ncbi.nlm.nih.gov/31804827/ | null | PROTACpedia | null | null | Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01
Instable (MSI).
Metastatic; Left supraclavicular lymph node;
Caucasian.
Space-flown cell line (cellonaut).
Cancer cell line | 16 | false | 24 | 0 |
C#Cc1cccc2cc(O)cc(-c3nc(OC)c4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-FWIBTM | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1cccc2cc(O)cc(-c3nc(OC)c4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-FWIBTM | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN(C)CC6CCN(c7ccc8c(c7)CN(C7CCC(=O)NC7=O)C8=O)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 550 | null | 100 | 1,000 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-GQ7KAX | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 25 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN(C)CC6CCN(c7ccc8c(c7)CN(C7CCC(=O)NC7=O)C8=O)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-GQ7KAX | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 25 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(C(=O)N7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 550 | null | 100 | 1,000 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-ZB5KH5 | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 26 | 0 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCC(C(=O)N7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-ZB5KH5 | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 26 | 0 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(CC(=O)N[C@@H](C(=O)N8C[C@@H](O)C[C@@H]8C(=O)NCc8ccc(-c9scnc9C)cc8)C(C)(C)C)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-AI4FTL | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 27 | 0 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(CC(=O)N[C@@H](C(=O)N8C[C@@H](O)C[C@@H]8C(=O)NCc8ccc(-c9scnc9C)cc8)C(C)(C)C)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-AI4FTL | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 27 | 0 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(CCC(=O)N[C@@H](C(=O)N8C[C@@H](O)C[C@@H]8C(=O)NCc8ccc(-c9scnc9C)cc8)C(C)(C)C)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-PQVQUK | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 28 | 0 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(CCC(=O)N[C@@H](C(=O)N8C[C@@H](O)C[C@@H]8C(=O)NCc8ccc(-c9scnc9C)cc8)C(C)(C)C)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-PQVQUK | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 28 | 0 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc(NC9CCC(=O)NC9=O)cc8)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-6OJA3R | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 29 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc(NC9CCC(=O)NC9=O)cc8)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 10 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-6OJA3R | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 29 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)C(=O)N(C8CCC(=O)N(C)C8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-C31VQV | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 30 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)C(=O)N(C8CCC(=O)N(C)C8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-C31VQV | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 30 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)C(=O)N(C8CCC(=O)NC8=O)C9)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-QD40BT | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 31 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)C(=O)N(C8CCC(=O)NC8=O)C9)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-QD40BT | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 31 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)C(=O)N(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-PKDI3W | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 30 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)C(=O)N(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-PKDI3W | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 30 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-8K0O8T | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | true | -1 | -1 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-8K0O8T | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | true | -1 | -1 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)N(C)C8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-8LKJXS | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)N(C)C8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-8LKJXS | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-01E67F | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-01E67F | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)[C@@H](C7CC7)C6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-9FS2K7 | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 32 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)[C@@H](C7CC7)C6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-9FS2K7 | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 32 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)n(C)c(=O)n9C8CCC(=O)NC8=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 100 | null | null | null | null | null | < | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-K56VML | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 33 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)n(C)c(=O)n9C8CCC(=O)NC8=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 50 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-K56VML | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 33 | 41 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6C(=O)C(F)(F)F)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | DC50 | nM | 1,000 | null | null | null | null | null | > | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-VGPZLG | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 0 |
C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6C(=O)C(F)(F)F)nc(OCC5(CN6CCN(CC7CCN(c8ccc9c(c8)CN(C8CCC(=O)NC8=O)C9=O)CC7)CC6)CC5)nc4c3F)c12 | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | CRBN | SW1990 | Dmax | % | 30 | null | 10 | 50 | null | null | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_1723 | Homo sapiens | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION (patent) | KRAS(G 12D/C/V) Western blot protein degradation assay
Cell lines SW1990 and GP2D that express KRAS(G12D), LU65A that expresses KRAS(G12C), and NCIH727 that expresses KRAS(G12V) were seeded in 6- or 12-well tissue culture plates, and after 1 hr, test compounds were added at various concentrations and incubated at 37°C/... | TPDdb | Western Blot | TPD-VGPZLG | African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*26
Stable (MSS) (Sanger).
Metastatic; Spleen;
Caucasian.
Epithelial cell of pancreas; CL=CL_0000083.
Cance... | -1 | false | 0 | 0 |
C/C(=C\C(=O)N[C@H]1CN(C(=O)CCCCCC#Cc2cccc3c2CN(C2CCC(=O)NC2=O)C3=O)CC[C@H]2CC[C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NC(c3ccccc3)c3ccccc3)N2C1=O)c1ccc(C(F)(F)P(=O)(O)O)cc1 | STAT3 | MAQWNQLQQLDTRYLEQLHQLYSDSFPMELRQFLAPWIESQDWAYAASKESHATLVFHNLLGEIDQQYSRFLQESNVLYQHNLRRIKQFLQSRYLEKPMEIARIVARCLWEESRLLQTAATAAQQGGQANHPTAAVVTEKQQMLEQHLQDVRKRVQDLEQKMKVVENLQDDFDFNYKTLKSQGDMQDLNGNNQSVTRQKMQQLEQMLTALDQMRRSIVSELAGLLSAMEYVQKTLTDEELADWKRRQQIACIGGPPNICLDRLENWITSLAESQLQTRQQIKKLEELQQKVSYKGDPIVQHRPMLEERIVELFRNLMKSA... | CRBN | MOLM-16 | DC50 | nM | 4,450 | null | null | null | null | 10 | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P40763 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_2120 | Homo sapiens | 10.1021/acs.jmedchem.9b01530; https://pubmed.ncbi.nlm.nih.gov/31715132/ | Degradation of total STAT3 and p-STAT3Y705 proteins in Molm-16/SU-DHL-1 cells after 4/16 h treatment | PROTAC-DB; PROTACpedia | null | null | African=2.33%; Native American=0%; East Asian, North=81.24%; East Asian, South=12.89%; South Asian=0%; European, North=0%; European, South=3.54%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*24
Stable (MSS) (Sanger).
In situ; Peripheral blood;
Japanese.
Cancer cell line | -1 | false | 34 | 0 |
C/C(=C\C(=O)N[C@H]1CN(C(=O)CCCCCC#Cc2cccc3c2CN(C2CCC(=O)NC2=O)C3=O)CC[C@H]2CC[C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NC(c3ccccc3)c3ccccc3)N2C1=O)c1ccc(C(F)(F)P(=O)(O)O)cc1 | p-STAT3-Y705 | MAQWNQLQQLDTRYLEQLHQLYSDSFPMELRQFLAPWIESQDWAYAASKESHATLVFHNLLGEIDQQYSRFLQESNVLYQHNLRRIKQFLQSRYLEKPMEIARIVARCLWEESRLLQTAATAAQQGGQANHPTAAVVTEKQQMLEQHLQDVRKRVQDLEQKMKVVENLQDDFDFNYKTLKSQGDMQDLNGNNQSVTRQKMQQLEQMLTALDQMRRSIVSELAGLLSAMEYVQKTLTDEELADWKRRQQIACIGGPPNICLDRLENWITSLAESQLQTRQQIKKLEELQQKVSYKGDPIVQHRPMLEERIVELFRNLMKSA... | CRBN | SU-DHL-1 | DC50 | nM | 10,000 | null | null | null | null | 16 | > | null | null | PROteolysis-TArgeting Chimera (PROTAC) | P40763 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | CVCL_0538 | Homo sapiens | 10.1021/acs.jmedchem.9b01530 | Degradation of total STAT3 and p-STAT3Y705 proteins in Molm-16/SU-DHL-1 cells after 4/16 h treatment | PROTAC-DB | null | null | African=3.76%; Native American=22.55%; East Asian, North=5.57%; East Asian, South=0%; South Asian=0%; European, North=43.3%; European, South=24.81%.
Gene fusion; HGNC; HGNC Mutation; HGNC; HGNC
A*02 A*02
Stable (MSS) (Sanger).
In situ; Pleural effusion;
Caucasian.
Cancer cell line | -1 | false | 34 | 0 |
C=C(C)c1ccc(C(=O)Nc2cc(F)cc(-c3ncnc4[nH]c(-c5ccc(C6CCN(CC7CCN(c8ccc(N9CCC(=O)NC9=O)cc8)CC7)CC6)cc5)cc34)c2C)c(F)c1 | BTK | MAAVILESIFLKRSQQKKKTSPLNFKKRLFLLTVHKLSYYEYDFERGRRGSKKGSIDVEKITCVETVVPEKNPPPERQIPRRGEESSEMEQISIIERFPYPFQVVYDEGPLYVFSPTEELRKRWIHQLKNVIRYNSDLVQKYHPCFWIDGQYLCCSQTAKNAMGCQILENRNGSLKPGSSHRKTKKPLPPTPEEDQILKKPLPPEPAAAPVSTSELKKVVALYDYMPMNANDLQLRKGDEYFILEESNLPWWRARDKNGQEGYIPSNYVTEAEDSIEMYEWYSKHMTRSQAEQLLKQEGKEGGFIVRDSSKAGKYTVSVF... | CRBN | null | DC50 | nM | 10.2 | null | null | null | null | null | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | Q06187 | Q96SW2 | MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTS... | null | Homo sapiens | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE (patent) | HTFR assay
After 6h treatment, add 10μl 4xlysis buffer to each well; seal the plate and incubate 30min at room temperature on a plate shaker; Once the cells are lysed, 16 μL of cell lysate are transferred to a PE 384-well HTRF detection plate; 4 μL of pre-mixed HTRF antibodies are added to each well; Cover the plate wi... | TPDdb | HTRF | TPD-X25T17 | null | 31 | false | 35 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCC(=O)NCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | NCI-H2030 | DC50 | nM | 6,400 | null | null | null | null | 24 | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1517 | Homo sapiens | https://pubmed.ncbi.nlm.nih.gov/32875077/ | null | PROTACpedia | null | null | African=0.43%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=2.87%; European, North=64.18%; European, South=32.52%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*11
Stable (MSS) (Sanger).
Metastatic; Lymph node;
Caucasian.
Cancer cell line | -1 | false | 36 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCC(=O)NCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | NCI-H2030 | Dmax | % | 85 | null | null | null | null | 72 | ~ | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1517 | Homo sapiens | https://pubmed.ncbi.nlm.nih.gov/32875077/ | null | PROTACpedia | null | null | African=0.43%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=2.87%; European, North=64.18%; European, South=32.52%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*11
Stable (MSS) (Sanger).
Metastatic; Lymph node;
Caucasian.
Cancer cell line | -1 | false | 36 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCC(=O)NCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS G12C | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | NCI-H2030 | DC50 | nM | 640 | null | null | null | null | 24 | null | null | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1517 | Homo sapiens | 10.1021/acscentsci.0c00411 | Degradation of KRAS G12C in NCI-H2030 cells after 24 h treatment | PROTAC-DB | null | null | African=0.43%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=2.87%; European, North=64.18%; European, South=32.52%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*11
Stable (MSS) (Sanger).
Metastatic; Lymph node;
Caucasian.
Cancer cell line | -1 | false | 36 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCC(=O)NCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS G12C | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | NCI-H2030 | Dmax | % | 85 | null | null | null | null | 24 | null | null | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1517 | Homo sapiens | 10.1021/acscentsci.0c00411 | Degradation of KRAS G12C in NCI-H2030 cells after 24 h treatment | PROTAC-DB | null | null | African=0.43%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=2.87%; European, North=64.18%; European, South=32.52%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*11
Stable (MSS) (Sanger).
Metastatic; Lymph node;
Caucasian.
Cancer cell line | -1 | false | 36 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCC(=O)NCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | NCI-H2030 | Dmax | % | 35 | null | null | null | null | 24 | ~ | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1517 | Homo sapiens | https://pubmed.ncbi.nlm.nih.gov/32875077/ | null | PROTACpedia | null | null | African=0.43%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=2.87%; European, North=64.18%; European, South=32.52%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*11
Stable (MSS) (Sanger).
Metastatic; Lymph node;
Caucasian.
Cancer cell line | -1 | false | 37 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCC(=O)NCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS G12C | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | NCI-H2030 | Dmax | % | 35 | null | null | null | null | 24 | null | null | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1517 | Homo sapiens | 10.1021/acscentsci.0c00411 | Degradation of KRAS G12C in NCI-H2030 cells after 24 h treatment | PROTAC-DB | null | null | African=0.43%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=2.87%; European, North=64.18%; European, South=32.52%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*11
Stable (MSS) (Sanger).
Metastatic; Lymph node;
Caucasian.
Cancer cell line | -1 | false | 37 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCC(=O)NCCOCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | NCI-H2030 | Dmax | % | 30 | null | null | null | null | 24 | ~ | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1517 | Homo sapiens | https://pubmed.ncbi.nlm.nih.gov/32875077/ | null | PROTACpedia | null | null | African=0.43%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=2.87%; European, North=64.18%; European, South=32.52%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*11
Stable (MSS) (Sanger).
Metastatic; Lymph node;
Caucasian.
Cancer cell line | -1 | false | 38 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCC(=O)NCCOCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS G12C | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | NCI-H2030 | Dmax | % | 30 | null | null | null | null | 24 | null | null | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1517 | Homo sapiens | 10.1021/acscentsci.0c00411 | Degradation of KRAS G12C in NCI-H2030 cells after 24 h treatment | PROTAC-DB | null | null | African=0.43%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=2.87%; European, North=64.18%; European, South=32.52%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*11
Stable (MSS) (Sanger).
Metastatic; Lymph node;
Caucasian.
Cancer cell line | -1 | false | 38 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | SW1573 | DC50 | nM | 880 | null | null | null | null | 24 | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1720 | Homo sapiens | https://pubmed.ncbi.nlm.nih.gov/32875077/ | null | PROTACpedia | null | null | African=0.36%; Native American=0.18%; East Asian, North=0.45%; East Asian, South=0%; South Asian=0%; European, North=66.92%; European, South=32.09%.
Gene deletion; HGNC; HGNC Gene deletion; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*02
Stable (MSS) (Sanger).
In situ... | -1 | false | 39 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | SW1573 | Dmax | % | 90 | null | null | null | null | 72 | ~ | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1720 | Homo sapiens | https://pubmed.ncbi.nlm.nih.gov/32875077/ | null | PROTACpedia | null | null | African=0.36%; Native American=0.18%; East Asian, North=0.45%; East Asian, South=0%; South Asian=0%; European, North=66.92%; European, South=32.09%.
Gene deletion; HGNC; HGNC Gene deletion; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*02
Stable (MSS) (Sanger).
In situ... | -1 | false | 39 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS G12C | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | SW1573 | DC50 | nM | 880 | null | null | null | null | 24 | null | null | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1720 | Homo sapiens | 10.1021/acscentsci.0c00411 | Degradation of KRAS G12C in SW1573 cells after 24 h treatment | PROTAC-DB | null | null | African=0.36%; Native American=0.18%; East Asian, North=0.45%; East Asian, South=0%; South Asian=0%; European, North=66.92%; European, South=32.09%.
Gene deletion; HGNC; HGNC Gene deletion; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*02
Stable (MSS) (Sanger).
In situ... | -1 | false | 39 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS G12C | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | SW1573 | Dmax | % | 90 | null | null | null | null | 24 | null | null | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1720 | Homo sapiens | 10.1021/acscentsci.0c00411 | Degradation of KRAS G12C in SW1573 cells after 24 h treatment | PROTAC-DB | null | null | African=0.36%; Native American=0.18%; East Asian, North=0.45%; East Asian, South=0%; South Asian=0%; European, North=66.92%; European, South=32.09%.
Gene deletion; HGNC; HGNC Gene deletion; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*02
Stable (MSS) (Sanger).
In situ... | -1 | false | 39 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | NCI-H2030 | DC50 | nM | 590 | null | null | null | null | 24 | null | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1517 | Homo sapiens | https://pubmed.ncbi.nlm.nih.gov/32875077/ | EC50/DC50/Dmax reported above were obtained using NCI-H2030 cells. DC50: 0.25~0.76uM; Dmax: ~75%-90%, specific value depends on the cell line. | PROTACpedia | null | null | African=0.43%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=2.87%; European, North=64.18%; European, South=32.52%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*11
Stable (MSS) (Sanger).
Metastatic; Lymph node;
Caucasian.
Cancer cell line | -1 | false | 40 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | NCI-H2030 | Dmax | % | 80 | null | null | null | null | 24 | ~ | numeric | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1517 | Homo sapiens | https://pubmed.ncbi.nlm.nih.gov/32875077/ | EC50/DC50/Dmax reported above were obtained using NCI-H2030 cells. DC50: 0.25~0.76uM; Dmax: ~75%-90%, specific value depends on the cell line. | PROTACpedia | null | null | African=0.43%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=2.87%; European, North=64.18%; European, South=32.52%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*11
Stable (MSS) (Sanger).
Metastatic; Lymph node;
Caucasian.
Cancer cell line | -1 | false | 40 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | SW1573 | DC50 | nM | 505 | null | 0.25 | 0.76 | null | 24 | null | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1720 | Homo sapiens | https://pubmed.ncbi.nlm.nih.gov/32875077/ | EC50/DC50/Dmax reported above were obtained using NCI-H2030 cells. DC50: 0.25~0.76uM; Dmax: ~75%-90%, specific value depends on the cell line. | PROTACpedia | null | null | African=0.36%; Native American=0.18%; East Asian, North=0.45%; East Asian, South=0%; South Asian=0%; European, North=66.92%; European, South=32.09%.
Gene deletion; HGNC; HGNC Gene deletion; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*02
Stable (MSS) (Sanger).
In situ... | -1 | false | 40 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | SW1573 | Dmax | % | 82.5 | null | 75 | 90 | null | 24 | ~ | range | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1720 | Homo sapiens | https://pubmed.ncbi.nlm.nih.gov/32875077/ | EC50/DC50/Dmax reported above were obtained using NCI-H2030 cells. DC50: 0.25~0.76uM; Dmax: ~75%-90%, specific value depends on the cell line. | PROTACpedia | null | null | African=0.36%; Native American=0.18%; East Asian, North=0.45%; East Asian, South=0%; South Asian=0%; European, North=66.92%; European, South=32.09%.
Gene deletion; HGNC; HGNC Gene deletion; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*02
Stable (MSS) (Sanger).
In situ... | -1 | false | 40 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS G12C | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | MIA PaCa-2 | DC50 | nM | 320 | null | null | null | null | 24 | null | null | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0428 | Homo sapiens | 10.1021/acscentsci.0c00411 | Degradation of KRAS G12C in NCI-H2030/MIA PaCa-2/SW1573 cells after 24 h treatment | PROTAC-DB | null | null | African=1.15%; Native American=0%; East Asian, North=3.82%; East Asian, South=0%; South Asian=8.7%; European, North=22.54%; European, South=63.79%.
Additional TP53 mutation in c.818G>A indicated incorrectly in PubMed=1630814.
Gene deletion; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*02,24; B*01,46; C*03. A*... | -1 | false | 40 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS G12C | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | MIA PaCa-2 | Dmax | % | 75 | null | null | null | null | 24 | null | null | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_0428 | Homo sapiens | 10.1021/acscentsci.0c00411 | Degradation of KRAS G12C in NCI-H2030/MIA PaCa-2/SW1573 cells after 24 h treatment | PROTAC-DB | null | null | African=1.15%; Native American=0%; East Asian, North=3.82%; East Asian, South=0%; South Asian=8.7%; European, North=22.54%; European, South=63.79%.
Additional TP53 mutation in c.818G>A indicated incorrectly in PubMed=1630814.
Gene deletion; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*02,24; B*01,46; C*03. A*... | -1 | false | 40 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS G12C | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | NCI-H2030 | DC50 | nM | 590 | null | null | null | null | 24 | null | null | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1517 | Homo sapiens | 10.1021/acscentsci.0c00411 | Degradation of KRAS G12C in NCI-H2030/MIA PaCa-2/SW1573 cells after 24 h treatment | PROTAC-DB | null | null | African=0.43%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=2.87%; European, North=64.18%; European, South=32.52%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*11
Stable (MSS) (Sanger).
Metastatic; Lymph node;
Caucasian.
Cancer cell line | -1 | false | 40 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS G12C | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | NCI-H2030 | Dmax | % | 80 | null | null | null | null | 24 | null | null | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1517 | Homo sapiens | 10.1021/acscentsci.0c00411 | Degradation of KRAS G12C in NCI-H2030/MIA PaCa-2/SW1573 cells after 24 h treatment | PROTAC-DB | null | null | African=0.43%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=2.87%; European, North=64.18%; European, South=32.52%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*11
Stable (MSS) (Sanger).
Metastatic; Lymph node;
Caucasian.
Cancer cell line | -1 | false | 40 | 0 |
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3CCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N | KRAS G12C | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | VHL | NCI-H23 | DC50 | nM | 250 | null | null | null | null | 24 | null | null | null | PROteolysis-TArgeting Chimera (PROTAC) | P01116 | P40337 | MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD | CVCL_1547 | Homo sapiens | 10.1021/acscentsci.0c00411 | Degradation of KRAS G12C in NCI-H23/NCI-H358 cells after 24 h treatment | PROTAC-DB | null | null | African=67.86%; Native American=2.12%; East Asian, North=2.83%; East Asian, South=0%; South Asian=0%; European, North=10.88%; European, South=16.3%.
Has lost chromosome Y.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*80 A*80
Stable (MSS) (Sanger).
In situ; Lung;
African America... | -1 | false | 40 | 0 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.